July 11, 2019 / 9:42 PM / 3 months ago

BRIEF-Amgen, Novartis And Banner Alzheimer's Institute Discontinue Clinical Research Program With Bace Inhibitor Cnp520 For Alzheimer's Prevention

July 11 (Reuters) - Amgen Inc:

* AMGEN, NOVARTIS AND BANNER ALZHEIMER’S INSTITUTE DISCONTINUE CLINICAL RESEARCH PROGRAM WITH BACE INHIBITOR CNP520 FOR ALZHEIMER’S PREVENTION

* AMGEN INC - SPONSORS CONCLUDED THAT POTENTIAL BENEFIT FOR PARTICIPANTS IN STUDIES DID NOT OUTWEIGH RISK

* AMGEN INC - INVESTIGATORS ARE BEING INFORMED OF DECISION TO DISCONTINUE STUDY

* AMGEN INC - AN ASSESSMENT OF UNBLINDED DATA DURING A REGULAR PRE-PLANNED REVIEW IDENTIFIED WORSENING IN SOME MEASURES OF COGNITIVE FUNCTION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below